GlobeNewswire by notified

SENISCA appoints Dr. Sarah Cole as Chief Executive Officer


SENISCA appoints Dr. Sarah Cole as Chief Executive Officer

Exeter, UK — 02 November 2023: SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces that Sarah Cole, PhD., who previously served as Chief Operating Officer, has been appointed to the role of Chief Executive Officer. Kirsty Semple, who served as launch Chief Executive Officer since January 2020, will continue to play a pivotal role in SENISCA’s future success and has assumed the role of Chief Operating Officer.

The changes to the management structure reflect SENISCA’s continuing rapid evolution from an early-stage spinout company towards becoming a clinical stage biotech focused on the development of a portfolio of novel senotherapeutics with broad applicability for the treatment of age-related disease.

Since her appointment as COO in March 2023, Dr. Cole has led strategic development, communications, and investor liaison activities at SENISCA. With over 20 years’ experience at the forefront of early-stage research and the venture capital funding of biotech firms, Sarah has held senior research positions in global pharmaceutical and biotechnology companies including Takeda and Transine Therapeutics, in addition to developing a successful career in life sciences investment at Takeda Ventures. Sarah is a recognised leader in strategic development, pipeline creation and the critical evaluation of business development opportunities, with a focus on the rapid evolution of early phase biotech. Sarah holds a PhD in Pharmacology from the University of Cambridge.

Dr. Sarah Cole, CEO of SENISCA, commented: “As launch CEO, Kirsty's leadership has provided the solid foundations that enable SENISCA to capitalise on the world-leading research of the Harries lab to develop novel senotherapeutics that target the causes and not simply the consequences of age-related disease. This is a hugely exciting time for the Company as we further develop and apply our unique platform technology to establish our presence as a leading developer of oligonucleotide senotherapeutics. I am delighted the Board has asked me to lead SENISCA. I look forward to drawing on my experience within the life sciences sector and working alongside Kirsty and the outstanding team, to guide SENISCA through the next stage in its evolution and ensure the Company achieves its full potential.

- Ends -

For more information
Sarah Cole
Chief Executive Officer, SENISCA

For media
ICR Consilium
Chris Welsh, Evi Useh


SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. The Company is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple pharmacological and skin health indications.

The Company is developing a portfolio of proprietary senotherapeutics, that target cell senescence for cellular rejuvenation in the treatment of age-related disease. SENISCA’s senotherapeutics specifically target the novel cellular pathway which causes cell rejuvenation and positively impacts markers of disease modification in patient-derived models. In line with the rapid evolution of the company, R & D activities are focused on IND data generation.

SENISCA’s platform technology has broad applicability for multiple age-related diseases including those of the eyes, lungs, joints, and brain. For many such diseases, current treatments are palliative rather than curative, with varying success rates. These diseases represent a high unmet medical need, are amenable to a local route of therapeutic administration and are driven by senescence. Targeting these specific diseases will streamline progress towards the clinic by avoiding potential pitfalls of systemic delivery.

SENISCA’s novel senotherapeutics will be mined and commercialized through partnership or co-development models that will sit alongside internal programmes. If you would like to learn more about SENISCA, please contact Jennie Jepperson, Executive Assistant at SENISCA (

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Schouw & Co. share buy-back programme, week 49 202311.12.2023 15:22:38 CET | Press release

On 15 November 2023, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 14 of 14 November 2023. Under the programme Schouw & Co. will acquire shares for up to DKK 75 million during the period 15 November 2023 to 1 March 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading dayNo. of sharesAverage priceAmount Accumulated until 1/12/2023 29,100 531.98 15,480,527 Monday, 4 December 2023 2,000 538.78 1,077,560 Tuesday, 5 December 2023 1,900 540.20 1,026,380 Wednesday, 6 December 2023 1,900 538.68 1,023,492 Thursday, 7 December 2023 2,000 538.62 1,077,240 Friday, 8 December 2023 2,000 541.92 1,083,840 In the period 4/12/2023 - 8/12/2023 9,800 539.64 5,288,512 Accumulated 15/11/2023 - 8/12/2023 38,900 533.91 20,769,039 Following the ab

Schouw & Co. aktietilbagekøbsprogram, uge 49 202311.12.2023 15:22:38 CET | pressemeddelelse

Den 15. november 2023 iværksatte Schouw & Co. et aktietilbagekøbsprogram som beskrevet i selskabsmeddelelse nr. 14 af 14. november 2023. I henhold til programmet vil Schouw & Co. i perioden fra 15. november 2023 til 1. marts 2024 købe egne aktier for et maksimalt beløb på 75 mio. kr. Aktietilbagekøbsprogrammet gennemføres i henhold til Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug (MAR) og Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016 ("Safe Harbour”-reglerne). HandelsdagAntal aktierGennemsnitlig kursBeløb Akkumuleret indtil 01/12 2023 29.100 531,98 15.480.527 mandag 4. december 2023 2.000 538,78 1.077.560 tirsdag 5. december 2023 1.900 540,20 1.026.380 onsdag 6. december 2023 1.900 538,68 1.023.492 torsdag 7. december 2023 2.000 538,62 1.077.240 fredag 8. december 2023 2.000 541,92 1.083.840 I perioden 4/12 2023 - 8/12 2023 9.800 539,64 5.288.512 Samlet i perioden 15/11 2023 - 8/12 2023 38.900 533,91 20.769.039 Ved

Meet Fortinet Advisor, a Generative AI Assistant that Accelerates Threat Investigation and Remediation11.12.2023 15:00:00 CET | Press release

Fortinet harnesses more than a decade of AI innovation and deep threat expertise to empower customers with a cutting-edge GenAI tool that upskills cybersecurity teams SUNNYVALE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today added Fortinet Advisor, a generative AI (GenAI) assistant, to its portfolio of more than 40 AI-powered offerings. AI has served as the backbone of the Fortinet Security Fabric and FortiGuard Labs threat intelligence and security services for more than a decade, and the implementation of GenAI is Fortinet’s latest innovation designed to protect customers and keep business operations online. The initial release of Fortinet Advisor will help support and guide security operations (SecOps) teams so they can investigate and remediate threats faster than ever before. “Fortinet has pioneered artificial intelligence innovation within cybersecurity, and to date, we’

BASF Environmental Catalyst and Metal Solutions (ECMS) signs agreement to acquire Arc Metal AB in Sweden11.12.2023 14:45:00 CET | Press release

Acquisition adds smelting capability to serve spent automotive catalyst customers in Europe, Middle East and Africa Complements ECMS recycling operations and global precious metal services Broadens range of materials that can be processed by ECMS Closing of transaction expected in early first quarter 2024 ISELIN, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BASF Environmental Catalyst and Metal Solutions (ECMS) has signed an agreement to purchase the assets of Arc Metal AB in Hofors, Sweden. The company currently conducts toll smelting and processing of spent automotive catalyst, among other services, and will further complement ECMS’s existing global precious metal recycling operations in Cinderford, UK, Seneca and Spartanburg, South Carolina, and Caldwell, Texas, USA. The closing of the transaction is expected early in the first quarter of 2024. “This investment will allow us to grow our recycling business in Europe and bring in best-in-class pyro-metallurgical technology providing flexib

Duck Creek Technologies Appoints Barbara Bufkin and Diane Fanelli to Board of Directors11.12.2023 14:30:00 CET | Press release

Accomplished executives bring decades of insurance and technology expertise to new board roles BOSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, has announced the appointments of Barbara Bufkin and Diane Fanelli to the company’s board of directors. Bufkin joins Duck Creek’s board with an extensive background in global (re)insurance, distribution, underwriting, and technology, advising companies in originating and fostering strategic partnerships. Fanelli is a global customer-centric operations leader known for her expertise in guiding global enterprise software teams and company growth. “Barbara and Diane are each accomplished and recognized experts in their respective fields, and they will add incredible value to guide Duck Creek’s long-term mission and business strategy,” says Mike Jackowski, CEO of Duck Creek Technologies. “Barbara’s and Diane’s areas of expe